S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
Log in

NASDAQ:ADMA - ADMA Biologics Stock Price, Forecast & News

$3.33
-0.17 (-4.86 %)
(As of 02/25/2020 04:00 PM ET)
Today's Range
$3.15
Now: $3.33
$3.62
50-Day Range
$3.32
MA: $3.98
$4.58
52-Week Range
$3.03
Now: $3.33
$6.31
Volume2.78 million shs
Average Volume1.54 million shs
Market Capitalization$197.53 million
P/E RatioN/A
Dividend YieldN/A
Beta2.62
ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMA
CUSIPN/A
Phone201-478-5552

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.99 million
Book Value$0.43 per share

Profitability

Net Income$-65,740,000.00
Net Margins-260.92%

Miscellaneous

Employees314
Market Cap$197.53 million
Next Earnings Date3/11/2020 (Estimated)
OptionableOptionable

Receive ADMA News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.


ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

How were ADMA Biologics' earnings last quarter?

ADMA Biologics Inc (NASDAQ:ADMA) announced its quarterly earnings data on Wednesday, November, 6th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.04. The biotechnology company had revenue of $7.22 million for the quarter, compared to analysts' expectations of $5.71 million. ADMA Biologics had a negative net margin of 260.92% and a negative return on equity of 203.21%. View ADMA Biologics' Earnings History.

When is ADMA Biologics' next earnings date?

ADMA Biologics is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for ADMA Biologics.

What guidance has ADMA Biologics issued on next quarter's earnings?

ADMA Biologics updated its FY 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $29.2-29.2 million, compared to the consensus revenue estimate of $25.38 million.

What price target have analysts set for ADMA?

6 Wall Street analysts have issued 1 year price targets for ADMA Biologics' shares. Their forecasts range from $4.00 to $14.00. On average, they anticipate ADMA Biologics' stock price to reach $10.20 in the next year. This suggests a possible upside of 206.3% from the stock's current price. View Analyst Price Targets for ADMA Biologics.

What is the consensus analysts' recommendation for ADMA Biologics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ADMA Biologics.

Has ADMA Biologics been receiving favorable news coverage?

Media headlines about ADMA stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ADMA Biologics earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for ADMA Biologics.

Who are some of ADMA Biologics' key competitors?

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Viking Therapeutics (VKTX), Gilead Sciences (GILD), Corbus Pharmaceuticals (CRBP), Verastem (VSTM), Exelixis (EXEL), Micron Technology (MU), Agile Therapeutics (AGRX), NVIDIA (NVDA), Opko Health (OPK) and SCYNEXIS (SCYX).

Who are ADMA Biologics' key executives?

ADMA Biologics' management team includes the folowing people:
  • Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 42)
  • Dr. Jerrold B. Grossman Ph.D., D.P.S., Co-Founder & Vice Chairman (Age 71)
  • Mr. Brian Lenz CPA, CPA, Exec. VP & CFO (Age 47)
  • Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 73)
  • Mr. James Hauert, Sr. VP of Commercialization & Strategy

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Schonfeld Strategic Advisors LLC (2.09%), State Street Corp (1.42%), Geode Capital Management LLC (1.21%), Motley Fool Asset Management LLC (0.90%), Goldman Sachs Group Inc. (0.59%) and Jane Street Group LLC (0.28%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Biotest Divestiture Trust, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Institutional Ownership Trends for ADMA Biologics.

Which institutional investors are selling ADMA Biologics stock?

ADMA stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Schonfeld Strategic Advisors LLC, CIBC World Markets Inc., Csenge Advisory Group and UBS Group AG. View Insider Buying and Selling for ADMA Biologics.

Which institutional investors are buying ADMA Biologics stock?

ADMA stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., State Street Corp, Bank of Montreal Can, Geode Capital Management LLC, California Public Employees Retirement System, Motley Fool Asset Management LLC, Raymond James & Associates and Windsor Creek Advisors LLC. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for ADMA Biologics.

How do I buy shares of ADMA Biologics?

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ADMA Biologics' stock price today?

One share of ADMA stock can currently be purchased for approximately $3.33.

How big of a company is ADMA Biologics?

ADMA Biologics has a market capitalization of $197.53 million and generates $16.99 million in revenue each year. The biotechnology company earns $-65,740,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. ADMA Biologics employs 314 workers across the globe.View Additional Information About ADMA Biologics.

What is ADMA Biologics' official website?

The official website for ADMA Biologics is http://www.admabiologics.com/.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]


MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  338 (Vote Outperform)
Underperform Votes:  231 (Vote Underperform)
Total Votes:  569
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe ADMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel